VF
TLIS

Virtu Financial’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Virtu Financial’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-717
Closed -$5K – 2262
2022
Q4 		$5K Buy
+717
New +$6.29K ﹤0.01% 1449
2022
Q3 		– Sell
-1,337
Closed -$16K – 2358
2022
Q2 		$16K Buy
+1,337
New +$21.1K ﹤0.01% 1372

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial's TLIS Position: Q1 2023 in Review

Virtu Financial sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2023, closing a stake of 717 shares — an estimated $5K sold.

Virtu Financial first reported a position in TLIS in Q2 2022 and held it in 2 quarters. The position peaked at $16K in Q2 2022. 22 funds tracked by Wall St. Rank hold TLIS as of Q1 2023.

  • Virtu Financial reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 717 Talis Biomedical Corporation Common Stock shares in Q1 2023, an estimated $5K.
  • Virtu Financial first reported a position in Talis Biomedical Corporation Common Stock in Q2 2022 and held it in 2 quarters.
  • Virtu Financial's Talis Biomedical Corporation Common Stock position peaked at $16K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.